Presentation of Virtual Tumou

RNS Number : 2124W

Physiomics PLC

16 November 2010

 



Physiomics plc

("Physiomics" or "the Company")

Physiomics to present the Virtual Tumour platform at the 2010 EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics"

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics", taking place at the Estrel Hotel and Convention Centre, Berlin, Germany on 16-19 November 2010.  Dr Eric Fernandez, Project Leader at Physiomics, will present the latest development of our Virtual Tumour platform.

The Virtual Tumour is a computer model that integrates pharmacokinetic and pharmacodynamic data in order to simulate the effect of anti-cancer drugs on growing tumours. Once calibrated with the data generated during research and development of a drug, this predictive tool can be used to rationally design and optimise schedules for drug combination. Coupled to our High Performance Computer, the model can simulate thousands of possible drug combination schedules that would be effectively impossible to investigate experimentally, and allow prioritisation of the most effective drug combinations.

The abstract ("The Virtual Tumour, a predictive simulation platform to optimize anti-cancer drug scheduling and combination", No 565) will be presented in the "Bioinformatics" poster session, scheduled 08:00 PM - 1:00 PM, 19 November 2010.

More information about the conference may be found at:

www.ecco-org.eu/Conferences-and-Events/EORTC-NCI-AACR-2010/page.aspx/1386

Dr Christophe Chassagnole, COO of Physiomics, said

"We are pleased to present this current development to the major oncology summit in Europe, which gathers the major players in the oncology field. We show here a validation study of our technology and we expect this will trigger interest from the conference attendees."

Enquiries:

Physiomics plc                                                  

Dr Christophe Chassagnole, COO

[phone]

WH Ireland Limited

Katy Mitchell

[phone]

Information on Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The models are used to optimise compound design, as well as to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

 

END

 

 

NRAFFLFMIFSSEDF